Lazard Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Lazard Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,664	Closed	-$1.09M	–	2116
2026 Q1	$1.09M	Sell	32,664 -15,781	-33%	-$619K	﹤0.01%	1128
2025 Q4	$2.24M	Sell	48,445 -8,000	-14%	-$439K	﹤0.01%	819
2025 Q3	$3.82M	Buy	56,445 +32,953	+140%	+$2.44M	0.01%	650
2025 Q2	$1.97M	Buy	+23,492	New	+$1.76M	﹤0.01%	1023

Lazard Asset Management's SLNO Position: Q2 2026 in Review

Lazard Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 32,664 shares — an estimated $1.09M sold.

Lazard Asset Management first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $3.82M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Lazard Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Lazard Asset Management sold 32,664 Soleno Therapeutics shares in Q2 2026, an estimated $1.09M.
Lazard Asset Management first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
Lazard Asset Management's Soleno Therapeutics position peaked at $3.82M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.